Tolterodine tartrate | CAS#124937-52-6 | 124937-51-5 | antimuscarinic

MedKoo Cat#: 326817 | Name: Tolterodine tartrate

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Tolterodine, also known as PNU-200583E, s an antimuscarinic drug that is used for symptomatic treatment of urinary incontinence. Tolterodine acts on M2 and M3 subtypes of muscarinic receptors whereas older antimuscarinic treatments for overactive bladder act more specifically on M3 receptors. Tolterodine, although it acts on all types of receptors, has fewer side effects than oxybutynin (M3 and M1 selective, but more so in the parotid than in the bladder) as tolterodine targets the bladder more than other areas of the body.

Chemical Structure

Tolterodine tartrate

CAS#124937-52-6 (tartrate)

Theoretical Analysis

MedKoo Cat#: 326817

Name: Tolterodine tartrate

CAS#: 124937-52-6 (tartrate)

Chemical Formula: C26H37NO7

Exact Mass:

Molecular Weight: 475.58

Elemental Analysis: C, 65.66; H, 7.84; N, 2.95; O, 23.55

Price and Availability

Size	Price	Availability	Quantity
5mg	USD 350.00
10mg	USD 550.00
25mg	USD 850.00

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

124937-51-5 (free base) 124937-52-6 (tartrate)

Synonym

PNU-200583E; PNU 200583E; PNU200583E; Tolterodine tartrate; Detrol LA; Detrusitol.

IUPAC/Chemical Name

(R)-2-(3-(diisopropylamino)-1-phenylpropyl)-4-methylphenol (2R,3R)-2,3-dihydroxysuccinate

InChi Key

TWHNMSJGYKMTRB-KXYUELECSA-N

InChi Code

InChI=1S/C22H31NO.C4H6O6/c1-16(2)23(17(3)4)14-13-20(19-9-7-6-8-10-19)21-15-18(5)11-12-22(21)24;5-1(3(7)8)2(6)4(9)10/h6-12,15-17,20,24H,13-14H2,1-5H3;1-2,5-6H,(H,7,8)(H,9,10)/t20-;1-,2-/m11/s1

SMILES Code

OC1=CC=C(C)C=C1[C@@H](C2=CC=CC=C2)CCN(C(C)C)C(C)C.O=C(O)[C@H](O)[C@@H](O)C(O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

related CAS# CAS#124937-51-5 (Tolterodine free base) CAS#124937-52-6 (Tolterodine tartrate)

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 475.58 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Gacci M, Sebastianelli A, Salvi M, Schiavina R, Brunocilla E, Novara G, De Nunzio C, Tubaro A, Oelke M, Gravas S, Carini M, Serni S. Tolterodine in the Treatment of Male LUTS. Curr Urol Rep. 2015 Sep;16(9):60. doi: 10.1007/s11934-015-0531-9. Review. PubMed PMID: 26149965. 2: Gacci M, Novara G, De Nunzio C, Tubaro A, Schiavina R, Brunocilla E, Sebastianelli A, Salvi M, Oelke M, Gravas S, Carini M, Serni S. Tolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review. BMC Urol. 2014 Oct 27;14:84. doi: 10.1186/1471-2490-14-84. Review. PubMed PMID: 25348235; PubMed Central PMCID: PMC4230346. 3: Medhi B, Mittal N, Bansal D, Prakash A, Sarangi SC, Nirthi B. Comparison of tolterodine with standard treatment in pediatric patients with non-neurogenic dysfunctional voiding/over active bladder: a systematic review. Indian J Physiol Pharmacol. 2013 Oct-Dec;57(4):343-53. Review. PubMed PMID: 24968572. 4: Angulo JC, Valpas A, Rejas J, Linden K, Kvasz M, Snedecor SJ. Cost effectiveness of fesoterodine and tolterodine for the treatment of overactive bladder with urge urinary incontinence in Spain and Finland. Clin Drug Investig. 2014 May;34(5):297-307. doi: 10.1007/s40261-014-0178-1. Review. PubMed PMID: 24567280. 5: Elterman DS, Chughtai B, Kaplan SA, Barkin J. Tolterodine for the treatment of urge urinary incontinence. Expert Opin Pharmacother. 2013 Oct;14(14):1987-91. doi: 10.1517/14656566.2013.823158. Epub 2013 Jul 26. Review. PubMed PMID: 23885788. 6: Omotosho T, Chen CC. Update on tolterodine extended-release for treatment of overactive bladder. Open Access J Urol. 2010 Nov 23;2:185-91. doi: 10.2147/OAJU.S7232. Review. PubMed PMID: 24198627; PubMed Central PMCID: PMC3818890. 7: Malhotra B, Gandelman K, Sachse R, Wood N, Michel MC. The design and development of fesoterodine as a prodrug of 5-hydroxymethyl tolterodine (5-HMT), the active metabolite of tolterodine. Curr Med Chem. 2009;16(33):4481-9. Review. PubMed PMID: 19835561. 8: Chung DE, Te AE. Tolterodine extended-release for overactive bladder. Expert Opin Pharmacother. 2009 Sep;10(13):2181-94. doi: 10.1517/14656560903167965. Review. PubMed PMID: 19663610. 9: Ulahannan D, Wagg A. The safety and efficacy of tolterodine extended release in the treatment of overactive bladder in the elderly. Clin Interv Aging. 2009;4:191-6. Epub 2009 May 14. Review. PubMed PMID: 19503781; PubMed Central PMCID: PMC2685240. 10: Salvatore S, Serati M, Bolis P. Tolterodine for the treatment of overactive bladder. Expert Opin Pharmacother. 2008 May;9(7):1249-55. doi: 10.1517/14656566.9.7.1249. Review. PubMed PMID: 18422481. 11: Bolge SC, McDonnell DD, Chen A, Wan GJ. Patient satisfaction with extended release tolterodine or oxybutynin in overactive bladder. Curr Med Res Opin. 2007 Aug;23(8):1903-12. Review. PubMed PMID: 17610806. 12: Kanofsky JA, Nitti VW. Tolterodine for treatment of overactive bladder. Urol Clin North Am. 2006 Nov;33(4):447-53, viii. Review. PubMed PMID: 17011380. 13: Rovner ES. Tolterodine for the treatment of overactive bladder: a review. Expert Opin Pharmacother. 2005 Apr;6(4):653-66. Review. PubMed PMID: 15934891. 14: Garely AD, Burrows L. Benefit-risk assessment of tolterodine in the treatment of overactive bladder in adults. Drug Saf. 2004;27(13):1043-57. Review. PubMed PMID: 15471509. 15: Abrams P. Evidence for the efficacy and safety of tolterodine in the treatment of overactive bladder. Expert Opin Pharmacother. 2001 Oct;2(10):1685-701. Review. PubMed PMID: 11825311. 16: Wefer J, Truss MC, Jonas U. Tolterodine: an overview. World J Urol. 2001 Nov;19(5):312-8. Review. PubMed PMID: 11760779. 17: Crandall C. Tolterodine: a clinical review. J Womens Health Gend Based Med. 2001 Oct;10(8):735-43. Review. PubMed PMID: 11703885. 18: Nilvebrant L. Clinical experiences with tolterodine. Life Sci. 2001 Apr 27;68(22-23):2549-56. Review. PubMed PMID: 11392625. 19: Clemett D, Jarvis B. Tolterodine: a review of its use in the treatment of overactive bladder. Drugs Aging. 2001;18(4):277-304. Review. PubMed PMID: 11341475. 20: Ruscin JM, Morgenstern NE. Tolterodine use for symptoms of overactive bladder. Ann Pharmacother. 1999 Oct;33(10):1073-82. Review. PubMed PMID: 10534221.